from the unreducing terminal and is followed by a unit selected from the group consisting of N-sulpho-D-glucosamine sulphate and N-acetyl-glucosamine in sulphated and unsulphated form in an amount sufficient for anticoagulation activity; and a pharmaceutical carrier.

4 (Amended). Pharmaceutical composition[s, characterized in that they] for preventative treatment or treatment of arterial thrombosis containing heparin fragments of the structure $(U\text{-}G)_n\text{-}I\text{-}G\text{-}(U\text{-}G)_m$ where n is 1 or 2 and m is 5 or 6, I is unsulphated L-iduronic acid, U is L-iduronic acid-2-O-sulphate and G is N-sulpho-D-glucosamine-6-O-sulphate in an amount sufficient for anticoagulation activity; and a pharmaceutical carrier.

Please add the following new claims:

5. The compostion of claim 3 or 4 wherein said carrier is water.

6. The composition of claim 3 or 4 which is in the form of an ointment.

END

REMARKS

Claims 1-7 are now in the application.

Claims 1-4, 6 and 7 are directed to the elected invention identified by the Examiner's Group I in the Office Action dated August 27, 1980. Claim 5, the other remaining claim in the application is directed to the nonelected invention identified by the Examiner's Group II and is concerned with the process for the preparation of the claimed compound. The Examiner is hereby granted authority to can-